Objectives: To evaluate the extent and quality of published pharmacoeconomic studies based in China. Methods: A systematic literature search was conducted using PubMed, Web of Science, Google Scholar, and China National Knowledge Infrastructure to identify pharmacoeconomic studies conducted in China. The keywords included different combinations of health economics, pharmacoeconomic, cost-effectiveness, and China. The inclusion criteria for the studies were: 1) original research articles; 2) written/published in English; 3) comparing a pharmaceutical to another pharmaceutical, treatment modality, or no treatment; and 4) conducted in China. The articles were reviewed by two independent reviewers using the 100-point Quality of Health Economic Studies scale for pharmacoeconomic studies. General and economic analysis information was collected from the articles. Results: A total of 20 studies were included, which were published in 11 different journals between 2006 and 2012 and had an average of 5 Ϯ 2 authors. The mean Quality of Health Economic Studies scale scores for pharmacoeconomic studies was 80 Ϯ 10. More than two-thirds of the authors resided in China (70%) and most had a medical background (90%). Most studies were published in foreign journals (not based in China) (90%), conducted cost-effectiveness (65%) or cost-utility analyses (65%), and used modeling as their study design (80%). Conclusions: China-based pharmacoeconomic studies written in English are limited in number, but, on average, are of good quality. Economic evaluation of pharmaceuticals should be encouraged in China because appropriate allocation of health care resources is important in a country where, despite economic growth, resources remain scarce relative to needs.
Introduction
Health care is a major concern for Chinese people. "It is too hard to seek health care and it is too expensive to pay for it!" is a common complaint from this large population with unmet medical needs. Several initiatives addressed this issue during the health care reforms of 2006. A government-run insurance program, the New Cooperative Medical Scheme, covered 86% of the rural population within a year of implementation. Attempts at supporting community health centers have been made to redirect urban patients from large hospitals to community health centers. Approximately $25 to $38 billion in government funding had been injected to provide universal basic health care [1] .
Although these initiatives mitigated some problems, there are still concerns due to the increasing cost and inefficiencies in the health care delivery system. van Doorslaer et al. [2] found that increased out-of-pocket health spending puts an additional 19% people below the poverty line. It has been estimated that 35% and 43% of urban and rural households, respectively, have difficulties in paying for their health care [3] . A study by Yip and Mahal [4] found that the cost of hospitalization can be nearly seven times the annual income of a low-income person in the rural areas and four times that in the urban areas. Liu and Mills [5] noted substantial overprescribing of medications and ordering of expensive services when remuneration to physicians was based on the quantity of services provided and the revenue generated by them. These unnecessary services drive up the costs associated with health care. Other problems involve inadequate insurance coverage, inequality, and inefficient use of scarce resources [6] .
Currently, China is going through an important phase of transformation in its health care system. Pharmacoeconomic research could be important at this crucial time by providing insights in managing health care costs and ensuring optimal use of scarce resources. This is especially important in a developing country such as China where the gap between required and available resources for health care is wide and continues to widen. For countries such as China, economic evaluations of health care resources can serve as useful tools in resource allocation and decision making. Such research could also help government health insurance programs in formulary decision making. The results assessing clinical outcomes and economic benefits could provide guidance to health care providers in selecting appropriate treatment plans and provide more transparency in decision making.
To our knowledge, no published study (in English) has systematically reviewed pharmacoeconomic studies conducted in China. Thus, the objective of this study was to evaluate the extent and quality of published pharmacoeconomic research in China.
Methods

Literature Search
A systematic search of the literature was conducted in December 2012 using PubMed, MEDLINE, Web of Science, and Google Scholar to identify pharmacoeconomic studies pertaining to China. Search terms included "pharmacoeconomic," "health economic," "cost," "cost-effectiveness analysis," "cost-minimization analysis," "cost-utility analysis," "cost-benefit analysis," "economics," "pharmacy," "pharmaceuticals," and "China." These keywords were used alone and in different combinations. The inclusion criteria for this study were as follows: 1) original studies; 2) carried out comparisons between pharmaceuticals, treatment modality, or against no treatment; 3) conducted in China (including Hong Kong); and 4) manuscript written/published in English. Studies comparing multiple countries were excluded. Articles were excluded if cost was not the main topic of the study. Reference lists of these articles were used to identify additional relevant articles. Full journal publication was required for a study to be included in this review; thus, meeting abstracts, letters to the editor, treatment guidelines or recommendations, expert opinion, and narrative reviews were excluded.
Two researchers (S.J. and X.M.) carried out the literature search using the English-based search engines and identified articles independently. They assessed the abstracts of the identified studies, and all abstracts that met the inclusion criteria were confirmed by a third researcher (P.D.). Full articles were then obtained for further evaluation. To examine and compare the number of articles written in Chinese that were not included in English-based search engines, a fourth researcher (L.Y.) used the China National Knowledge Infrastructure search engine to determine the number of articles written in Chinese up to 2012 using the same key words in Chinese.
Evaluation of Studies
A data collection form similar to the one developed by Gavaza et al. [7] , which has been used in several previous studies [8] [9] [10] , was used to collect general and economic information. General information included the total number of authors for the study, country of residence of the primary author, primary training of first author, year of publication of the study, journal in which the study was published, and type of publication. Economic information included type of costs, perspective of study, method of economic evaluation defined in study, study design, primary outcomes, type of data, disease state investigated, funding source, type of medical function, and the decision reached on whether treatment was cost-effective.
We used the Quality of Health Evaluation Studies (QHES) scale to assess full pharmacoeconomic studies [11, 12] . The QHES scale is a 16-item scale covering evaluation of study objectives, perspective, economic model, study design, and methodology. Each item is weighted appropriate to its importance in assessing quality. The QHES scale is a 100-point scale, with lower scores representing poor quality. A modified version of the Quality of Health Economic Survey instrument was used. Instead of using a zero versus full-score technique, three scoring points-full score, a midpoint score, or a zero-were used [8] . Two blinded reviewers assessed each article independently. All disagreements were resolved through discussions and assessment by a third reviewer. If the difference between the scores given by the two reviewers exceeded 10, it was passed to a third reviewer for further evaluation. In this case, the final score of the article was defined as the average score of the third reviewer and a closer score given by either reviewer.
Statistical Analysis
Descriptive statistics were reported for all the variables. The differences in QHES scale scores by variables (country of residence of the primary author, type of publication, geographic location, funding source, and type of medical function) were compared using independent sample t tests. The difference in QHES scale scores by type of data collection was compared using analysis of variance. The relationship between the QHES scale and the number of authors and the year of publication was assessed using Pearson's correlation coefficient. The alpha level was set at 0.05. All statistical analyses were conducted using SPSS version 20.
Results
The literature search using both English-based and Chinesebased search engines identified almost 6000 (5943) abstracts, but only 97 were available in English. After reviewing the abstracts of these 97 articles, 62 articles were excluded because of being multiple-country comparisons (n ¼ 13), having no cost analyses (n ¼ 36), being a cost-of-illness study (n ¼ 7), or a review article (n ¼ 6). Fifteen studies were further excluded because although the abstract was available in English, the full article was written in Chinese (n ¼ 11) and the study did not compare pharmaceutical products (n ¼ 4). Therefore, a total of 20 studies were included for further evaluation ( Fig. 1 and Table 1 ).
The earliest article was published in 2006, and the latest one was published in 2012 (Fig. 2) . The 20 articles were published in 11 different journals based in the United Kingdom (n ¼ 9), the United States (n ¼ 5), China (n ¼ 2), The Netherlands (n ¼ 2), and Japan (n ¼ 2). More than half (60%; n ¼ 12) of the articles were published in medical journals, and the other articles (40%; n ¼ 8) were published in health/medical economic journals. Articles had an average of five authors (mean 5 Ϯ 2). On the basis of institutional affiliation, most of the primary authors (i.e., first authors) were from China (70%; n ¼ 14) and had medical or clinical training (90%; n ¼ 18). Nationwide studies accounted for 70% of the studies (n ¼ 14), and the rest were subnational studies ( Table 2) .
The articles discussed various disease states including cancer
, and enterovirus71 infection (n ¼ 1). More than half of the studies (n ¼ 13; 65%) assessed disease treatment. The most common perspective was the third-party payer (n ¼ 12, 60%). Economic evaluation was the primary objective for all the included studies. Most of the studies (n ¼ 13; 65%) conducted cost-effectiveness analysis, and 10 articles (50%) conducted both cost-effectiveness analysis and cost-utility analysis. Three articles (15%) conducted costminimization analysis, and only one article conducted costbenefit analysis. Most studies used modeling (n ¼ 16; 80%) for their analyses. All the studies included direct medical costs, but only two (10%) included direct nonmedical costs, and two (10%) included indirect costs. In addition, 18 (90%) studies used secondary data, 10 (50%) studies used primary data, and 8 (40%) studies used both primary and secondary data. Most studies were funded by government (35%) or the pharmaceutical industry (30%) ( Table 3) .
The mean QHES scale scores for the 20 pharmacoeconomic studies was 80 Ϯ 10 out of 100, ranging from 59 to 96. Although none of the QHES scale comparisons (Table 4) were statistically significantly different, articles with first authors residing in foreign countries had a slightly higher mean QHES scale score than did those written by Chinese authors (82 vs. 80); articles that were published in health/medical economic journals had a higher QHES scale score than did those published in medical journals (83 vs. 79); subnational studies had a higher QHES scale score than did national studies (81 vs. 80); and industry-funded studies had a slightly higher score than did nonindustry studies (81 vs. 80).
Discussion
General and Economic Characteristics
In this study, the characteristics and quality of pharmacoeconomic studies in China that were available in English were summarized and presented. Similar to the articles that reviewed published studies from Russia (n ¼ 16) [9] , India (n ¼ 29) [8] , and Zimbabwe (n ¼ 26) [7] , our study had a low number of published full pharmacoeconomic studies (n ¼ 20). This number is lower than the number of reviews from other Asian countries such as Korea (n ¼ 45) [13] and Thailand (n ¼ 41) [14] , although it is acknowledged that we used stricter inclusion criteria. Although the earliest article based on the search was published in 1990, these early studies were mostly written in Chinese and were of low quality. The earliest study based on our criteria (available in English) was published in 2006. In addition, as shown in Fig. 2 , there was a reduction in the number of articles from 2010 to 2012. This is possibly due to the development of pharmacoeconomic journals in Chinese and the transfer of publications to Chinese journals. We found a large number (n ¼ 5846) of abstracts through our literature search that were written in Chinese. It was not within the scope of this study to assess the quality of articles written in Chinese. The preference for Chinese language publications for Chinese authors is likely because Chinese is the language predominantly used for academic and government communication in China because it is more widely understood compared with English. In addition to the language issues mentioned above, the limited number of English-based pharmacoeconomic studies in China is likely due to the unavailability of retrospective data or difficulty in conducting studies in which primary data are collected. This is supported by the fact that most of the studies (80%) used modeling. This rate is closest to that reported in the Korean study (47%) but still much higher. In modeling studies, variables were estimated from hospital data, expert options, and literature. Although justifications for data extraction were stated in 80% of the modeling studies, caution should still be exercised when interpreting the results. Most of the models were built in European countries and adapted to the Chinese studies. Although the modeling studies aim to use as much Chinese data as possible, which is obtained from local institutes such as hospitals, oftentimes because of the paucity of these data, some non-Chinese estimates are extracted from the literature. This highlights the need for collection/availability of more Chinese data at the local level to improve the representativeness and usefulness of the pharmacoeconomic studies.
In addition, little is known about the extent of pharmacoeconomic education in China [15] . To our knowledge, pharmacoeconomics is not one of the mandatory courses in most of the pharmacy schools and may be neglected in pharmacy schools in China. It is even more limited in pharmacy-related undergraduate education. The inadequacy of pharmacoeconomic education Fig. 1 -Article selection process. *5943 abstracts were also found by the Chinese search engine but were excluded in our study because they were not available in English. 
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in China could be another reason for the low number of publications. Lack of attention to health economic evaluations could be another contributing factor. After the health care reforms in 2006 were passed to help address the inefficiencies in the system and the affordability problems, pharmacoeconomic evaluations have increased substantially. The overall extent of pharmacoeconomic studies in China, however, is still limited compared with that in other Asian countries. At this time, there are no mandatory requirements for pharmacoeconomic assessments, although these evaluations have been included in a recent health care reform plan. Pharmacoeconomic evaluation can have a substantial impact on several aspects of the health care reform in China (2009), such as guidance of drug pricing, promotion of health insurance reimbursement, and rational use of drugs. In addition, pharmacoeconomics can provide strong evidence for the selection of essential drugs for the National Essential Drug List, as well as the best therapy for patients. Guidelines for China have been published on the International Society of Pharmacoeconomics and Outcomes Research Web site [16] .
The study results showed that only a small proportion of the articles were published in domestic (i.e., Chinese) journals (n ¼ 2 or 10%). This rate is lower than that for reviews from other Asian countries such as Thailand (33%) [14] and India (31%) [8] , but similar to that for Nigeria (14%) [10] . This suggests that China is lagging behind other Asian countries in the availability of domestic English language journals in which to publish pharmacoeconomic studies. In addition, perhaps pharmacoeconomic studies are not given a high priority by the existing Chinese journals that are available in English. This also raises the question whether the remaining 90% of the pharmacoeconomic studies published in foreign journals are reaching the intended audience-Chinese health care providers and decision makers. Because 70% of the first authors resided in China, the accessibility to foreign journals for Chinese researchers and clinicians might be an issue.
Cost-effectiveness (65%) and cost-utility (65%) analyses were the most frequently used methods of economic evaluation. Only one study conducted a cost-benefit analysis. Cost-benefit studies are complex, and the low number of cost-benefit studies may reflect the lack of knowledge and experience in using this method.
According to He et al. [17] , the nonaccidental leading causes of death in China are vascular diseases (cardiovascular and cerebrovascular), cancer, and infectious disease. Vascular diseases and cancer are also the most burdensome diseases. The most common diseases studied in our review were cancer (n ¼ 7), infectious disease (n ¼ 4), and cardiovascular disease (n ¼ 3), which are consistent with the top causes of death in China. This result shows that pharmacoeconomic studies in China have been focusing on the most burdensome diseases.
A higher percentage (85%) of studies listed the funding source when compared with reviews from Thailand (68%) [14] , Nigeria (45%) [10] , and Zimbabwe (35%) [7] . This may indicate a better transparency in the conduct of research and perhaps more reliability in the results. The two most common sources of CUA QALY CBA, cost-benefit analysis; CEA, cost-effectiveness analysis; CMA, cost-minimization analysis; CUA, cost-utility analysis; DALY, disabilityadjusted life-years; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; LYG, life-year gained; LYS, life-year saved; QALY, quality-adjusted life-year. Fig. 2 -Number of articles published in each year. 
funding in China are the government (35%) and the pharmaceutics industry (30%).
Quality of the Studies
In general, the studies included in this review were of high quality (QHES scale score ¼ 80 out of 100). The general and economic characteristics did not significantly relate with the quality of studies. This could be likely due to the relatively small sample size. To provide guidance and ensure the quality of future pharmacoeconomic studies, a new checklist for health carerelated economic publications-the Consolidated Health Economic Evaluation Reporting Standards-was unveiled and discussed at the Annual International Society of Pharmacoeconomics and Outcomes Research meeting in May 2013 [18] . Future reviewers and authors are encouraged to use this checklist.
Limitations
A limitation of this study is the small number of articles that met the inclusion criteria. Most of the articles found in the literature search were excluded because they were not available in English. In addition, some abstracts were available in English but the fulltext articles were in Chinese and thus excluded. This exclusion criterion reduces our ability to capture the overall quality of studies in China. We also excluded the studies that did not conduct any cost comparisons, which further reduced the number of studies. Another limitation is the potential threat of publication bias because only published studies were included. Previous studies have shown that positive results are more likely than negative results to get published [19] . Also, because only published research was included, any reports, agency work, dossiers, consulting documents, and so forth that may be used by clinicians and decision makers were not included. Finally, other reviewers may score the studies differently, which could lead to variation in the results.
Conclusions
To our knowledge, this is the first systematic review of phamacoeconomic studies conducted in China. Overall, the number of China-based pharmacoeconomic studies written in English was limited, but, on average, of good quality. * Total is more than 100% because some studies fell into more than one category.
